Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Real-world retrospective comparison showing lenvatinib superior to sorafenib on OS and treatment durability after first-line immunotherapy in HCC, but observational design and potential confounding limit strength of evidence.
A single-center retrospective tissue microarray study with exploratory aims, no control group, and hypothesis-generating findings that establish target expression prevalence but lack sufficient power or design to establish clinical utility or practice-changing guidance.
A single case report with a favorable outcome in HER2-positive gallbladder cancer treated with trastuzumab emtansine; raises a hypothesis for future investigation but lacks comparative design, control, or replication.
This is a structured narrative review synthesizing evidence and international guidelines on surgical management of borderline resectable pancreatic cancer in the neoadjuvant therapy era, offering a practical decision-making framework rather than reporting original trial data.
A narrative review synthesizing current evidence on immunotherapy in advanced biliary tract cancer, highlighting established standards (TOPAZ-1, KEYNOTE-966), emerging biomarkers, and investigational approaches rather than reporting original trial results.
A single case report of advanced HCC with rupture treated with combination immunotherapy and successfully transplanted; demonstrates feasibility but lacks comparator, control group, and generalizability needed to establish efficacy or change practice.
A multi-algorithm machine learning signature study with external validation across four datasets and functional validation of a candidate gene, showing clear prognostic separation but limited by retrospective cohort design and surrogate endpoints rather than prospective clinical outcomes.
A multicenter retrospective real-world study with propensity weighting showing clinically meaningful improvements in response rates, PFS, and OS for a novel embolic agent versus standard care, but limited by retrospective design and real-world (non-randomized) conduct.